Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Liabilities: 2020-2025

Historic Total Liabilities for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $18.4 million.

  • SAB Biotherapeutics' Total Liabilities rose 8.76% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 8.76%. This contributed to the annual value of $18.2 million for FY2024, which is 31.59% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Total Liabilities stood at $18.4 million, which was up 1.44% from $18.1 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Total Liabilities ranged from a high of $42.6 million in Q4 2021 and a low of $7.9 million during Q1 2021.
  • Over the past 3 years, SAB Biotherapeutics' median Total Liabilities value was $18.1 million (recorded in 2025), while the average stood at $17.9 million.
  • Within the past 5 years, the most significant YoY rise in SAB Biotherapeutics' Total Liabilities was 245.40% (2022), while the steepest drop was 53.40% (2022).
  • SAB Biotherapeutics' Total Liabilities (Quarterly) stood at $42.6 million in 2021, then crashed by 53.40% to $19.8 million in 2022, then surged by 34.24% to $26.6 million in 2023, then slumped by 31.59% to $18.2 million in 2024, then increased by 8.76% to $18.4 million in 2025.
  • Its Total Liabilities stands at $18.4 million for Q3 2025, versus $18.1 million for Q2 2025 and $16.7 million for Q1 2025.